Mary de Croos, MD
Endocrinology, Diabetes & Metabolism · Owensboro, KYNPI 1972957157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,228 and has fallen 83.2% since, to $206 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 189 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$541
- Lilly USA, LLC$524
- Amgen$361
- Insulet Corporation$277
- AstraZeneca$257
- Corcept Therapeutics$207
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,425100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $541 |
| Lilly USA, LLC | 29 | $524 |
| Amgen(2 entities) | 22 | $361 |
| Insulet Corporation | 14 | $277 |
| AstraZeneca(2 entities) | 15 | $257 |
| Corcept Therapeutics | 11 | $207 |
| Sanofi-aventis U.S. LLC | 6 | $192 |
| Medtronic | 10 | $186 |
| Tandem Diabetes Care, Inc. | 6 | $135 |
| Boehringer Ingelheim | 7 | $127 |
| Ultragenyx Pharmaceutical Inc. | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Bayer | 4 | $63 |
| Kyowa Kirin, Inc. | 3 | $61 |
| Novartis | 3 | $52 |
| Dexcom, Inc. | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Nevro Corp. | 2 | $35 |
| AbbVie | 2 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| BETA Bionics, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$124
How this compares
$3,439 in reported general payments places this provider in the 45th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 410 | $483,416 |
| MounjaroTirzepatide | 188 | $221,100 |
| JardianceEmpagliflozin | 216 | $208,046 |
| TrulicityDulaglutide | 123 | $147,680 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $82,344 |
| FarxigaDapagliflozin Propanediol | 57 | $60,258 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $41,829 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $40,909 |
| JanuviaSitagliptin Phosphate | 29 | $30,323 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $29,684 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 16 | $29,503 |
| Novolog FlexpenInsulin Aspart | 91 | $19,661 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $16,845 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 18 | $16,592 |
| FiaspInsulin Aspart (Niacinamide) | 26 | $15,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp | $541 | $498,768436 claims |
| Lilly USA, LLCMounjaro, Trulicity | $524 | $368,780311 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $127 | $220,766228 claims |
| AstraZenecaFarxiga | $257 | $60,25857 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $192 | $29,68432 claims |
| AbbVieSynthroid | $33 | $1,53119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Owensboro
- Betty VillafuerteOwensboro$8K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Moussa AlhajAshland$111K
- Mehdi PoorkayLouisville$81K
- Lyle MyersLexington$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.